

Caspofungin (Candidas[®])
Merck Sharp & Dohme Ltd (MSD)

(No. 74/03)

Indication: Invasive candidiasis in non-neutropenic adults.

Summary of Recommendation

12 January, 2004

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The recommendation is summarised as follows:

Advice: following a full submission.

Accepted for restricted use within NHS Scotland.

Caspofungin provides an additional agent for the treatment of invasive candidiasis. Its use should be restricted to patients with fluconazole-resistant *Candida* infection who do not respond to, or cannot tolerate amphotericin B therapy or who are at an increased risk of serious side effects with amphotericin (eg. transplant patients, especially those receiving bone marrow transplants).

Professor David H Lawson
Chairman